Abstract

This study aimed to examine the agreement of the serum amyloid A (SAA) values determined using the ELISA test and the nephelometric automated method. This study included 80 serum samples obtained from patients with COVID-19. Samples were determined using ELISA and the nephelometric method. Wilcoxon signed ranks test showed a statistically significant difference in the calculated median values (Z = −2.432, p = 0.015). The correlation between methods was statistically significant (r = 0.603, p < 0.0001). Bland Altman analysis showed a bias of 56.6 mg/L and a relative bias of 7.4% between the methods. The results of this study indicate that further studies are needed that will examine the compliance between the ELISA and the nephelometric method for determining SAA, and the results must be carefully interpreted based on the method used.

摘要

本研究旨在检查使用 ELISA 测试和比浊法自动方法确定的血清淀粉样蛋白 A (SAA) 值的一致性。该研究包括从 COVID-19 患者获得的 80 份血清样本。使用 ELISA 和比浊法测定样品。Wilcoxon 符号秩检验显示计算的中值具有统计学显着差异 ( Z  = −2.432, p  = 0.015)。方法之间的相关性具有统计学意义 ( r  = 0.603, p < 0.0001）。Bland Altman 分析显示两种方法之间的偏差为 56.6 mg/L，相对偏差为 7.4%。这项研究的结果表明，需要进一步的研究来检查 ELISA 和比浊法确定 SAA 的一致性，并且必须根据所使用的方法仔细解释结果。